Encorafenib | hsa00030 | Pentose phosphate pathway | 1.19E-02 | 2 | P52209, P37837 | PGD, TALDO1 | More | |
Encorafenib | hsa00514 | Other types of O-glycan biosynthesis | 1.42E-02 | 2 | P15907, Q8N4A0 | ST6GAL1, GALNT4 | More | |
Encorafenib | hsa00670 | One carbon pool by folate | 1.33E-02 | 2 | P04818, Q99707 | TYMS, MTR | More | |
Encorafenib | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04012 | ErbB signaling pathway | 6.63E-03 | 4 | P16333, P19174, P01106, P04049 | NCK1, PLCG1, MYC, RAF1 | More | |
Encorafenib | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04071 | Sphingolipid signaling pathway | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04110 | Cell cycle | 2.06E-02 | 6 | Q9UBD5, P06493, Q14683, P30304, P33981, P01106 | ORC3, CDK1, SMC1A, CDC25A, TTK, MYC | More | |
Encorafenib | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04330 | Notch signaling pathway | 2.29E-02 | 2 | Q92769, Q92830 | HDAC2, KAT2A | More | |
Encorafenib | hsa04340 | Hedgehog signaling pathway | 4.50E-02 | 2 | O43791, P30279 | SPOP, CCND2 | More | |
Encorafenib | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04510 | Focal adhesion | 6.96E-03 | 4 | Q15942, P30281, P04049, Q9NQU5 | ZYX, CCND3, RAF1, PAK6 | More | |
Encorafenib | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04613 | Neutrophil extracellular trap formation | 2.65E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04650 | Natural killer cell mediated cytotoxicity | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04926 | Relaxin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05014 | Amyotrophic lateral sclerosis | 4.20E-02 | 5 | Q71U36, Q13148, P21796, P43243, P84103 | TUBA1A, TARDBP, VDAC1, MATR3, SFRS3 | More | |
Encorafenib | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.75E-02 | 2 | Q99437, P41240 | ATP6V0B, CSK | More | |
Encorafenib | hsa05132 | Salmonella infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05162 | Measles | 3.34E-02 | 4 | P11142, Q13191, P30279, O43318 | HSPA8, CBLB, CCND2, MAP3K7 | More | |
Encorafenib | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05169 | Epstein-Barr virus infection | 2.76E-02 | 5 | Q92769, O43318, P30101, Q13761, P30279 | HDAC2, MAP3K7, PDIA3, RUNX3, CCND2 | More | |
Encorafenib | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05212 | Pancreatic cancer | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Encorafenib | hsa05231 | Choline metabolism in cancer | 4.44E-03 | 4 | P04049, Q9Y259, P19174, P49619 | RAF1, CHKB, PLCG1, DGKG | More | |
Encorafenib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |